gth 4/20/06 4239-61997-01 514678.doc E-147-1999/1-US-01

PATENT
Attorney Reference Number 4239-61997-01



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

re application of: Klinman et al.

Patent No. 6,977,245

Issued: December 20, 2005 Application No. 10/068,160

Filed: February 6, 2002 Confirmation No. 9731

For:

OLIGODEOXYNUCLEOTIDE AND ITS USE

TO INDUCE AN IMMUNE RESPONSE

Examiner: Dave Nguyen

Art Unit: 1623

Attorney Reference No. 4239-61997-01

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: COMMISSIONER FOR PATENTS, ATTN: CERTIFICATE OF CORRECTIONS BRANCH, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the

date shown below.

Attorney or Agent for Applicant(s)

Date Mailed April 20, 2006

COMMISSIONER FOR PATENTS

ATTN: CERTIFICATE OF CORRECTIONS BRANCH

P.O. BOX 1450

ALEXANDRIA, VA 22313-1450

Certificate

APR 2 7 2006

of Correction

TRANSMITTAL LETTER

Enclosed for filing in the application referenced above are the following:

∠ Letter Requesting Certificate of Correction.

Certificate of Correction.

The Director is hereby authorized to charge any fees that may be required, or credit over-payment, to Account No. 02-4550. A copy of this sheet is enclosed.

Please return the enclosed postcard to confirm that the items listed above have been received.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

One World Trade Center, Suite 1600

121 S.W. Salmon Street Portland, Oregon 97204

Telephone: (503) 595-5300 Facsimile: (503) 595-5301

cc:

Docketing

Gwynedd Warren, Ph.D. Registration No. 45,200

MAY 1 2006



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

application of: Klinman et al.

atent No. 6,977,245

Issued: December 20, 2005 **Application No. 10/068,160** Filed: February 6, 2002

Confirmation No. 9731

OLIGODEOXYNUCLEOTIDE AND ITS USE For:

TO INDUCE AN IMMUNE RESPONSE

Examiner: Dave Nguyen.

Art Unit: 1623

Attorney Reference No. 4239-61997-01

COMMISSIONER FOR PATENTS

ATTN: CERTIFICATE OF CORRECTIONS BRANCH

P.O. BOX 1450

ALEXANDRIA, VA 22313-1450

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: COMMISSIONER FOR PATENTS, ATTN: CERTIFICATE OF CORRECTIONS BRANCH, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Attorney or Agent for Applicant(s)

Date Mailed April 20,

TRANSMITTAL LETTER

Enclosed for filing in the application referenced above are the following:

Letter Requesting Certificate of Correction.

Certificate of Correction.

X The Director is hereby authorized to charge any fees that may be required, or credit overpayment, to Account No. 02-4550. A copy of this sheet is enclosed.

冈 Please return the enclosed postcard to confirm that the items listed above have been received.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

One World Trade Center, Suite 1600

121 S.W. Salmon Street Portland, Oregon 97204

Telephone: (503) 595-5300 Facsimile: (503) 595-5301

cc:

Docketing

Gwynedd Warren, Ph.D.

Registration No. 45,200

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APR 25 2008 H. Ingre application of: Klinman et al.

Patent No. 6,977,245

Issued: December 20, 2005 **Application No.** 10/068,160

Filed: February 6, 2002 Confirmation No. 9731

For: OLIGODEOXYNUCLEOTIDE AND ITS

USE TO INDUCE AN IMMUNE

RESPONSE

Examiner: Dave Nguyen

Art Unit: 1623

Attorney Reference No. 4239-61997-01

COMMISSIONER FOR PATENTS

ATTN: CERTIFICATE OF CORRECTIONS BRANCH

P.O. BOX 1450

ALEXANDRIA, VA 22313-1450

REQUEST FOR CERTIFICATE OF CORRECTION

Applicants hereby request correction of certain minor errors in the abovereferenced application. It is believed that no fee is required for this Request, as all of the errors are attributable to the Patent Office. The Director is hereby authorized to charge any fees that may be required, or credit over-payment to the deposit account referenced in the accompanying transmittal form.

The following requested corrections are indicated on the accompanying Form 1050:

In the claims:

In claim 1, please insert the word "stabilized" between the words "isolated" and "oligodeoxynucleotide" in line 1, and change "SEQ ID NO:15" to SEQ ID NO:14" in line 6.

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: COMMISSIONER FOR PATENTS, ATTN: CERTIFICATE OF CORRECTIONS BRANCH, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Attorney or Agent for Applicant(s)

Date Mailed April 20, 2006

1 2006

1.000

In claim 7, please delete the word "of" between the words "oligodeoxynucleotide" and "delivery" in line 1.

REMARKS

Correction of claims 1 and 7 is requested to remedy certain minor printing errors that were discovered in comparing the printed patent to the records in the Attorneys' files. In particular, claim 1, line 1 is corrected to insert the word "stabilized" between the terms "isolated" and "oligodeoxynucleotide." Line 6 is corrected to indicate that the sequence is designated as SEQ ID NO:14 and not as SEQ ID NO:15. In claim 7, the word "of" between the terms "oligodeoxynucleotide" and "delivery" is deleted in line 1.

All of the above errors are attributable to the Patent Office, and a Certificate of Correction is enclosed in duplicate to make formal notice of the errors in the referenced patent.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

One World Trade Center, Suite 1600

121 S.W. Salmon Street Portland, Oregon 97204

Telephone: (503) 595-5300 Facsimile: (503) 595-5301

cc: Docketing

Gwynedd Warren, Ph.D. Registration No. 45,200

1 2006

Staple Here Only

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO. : 6,977,245

DATED : December 20, 2005

INVENTOR(S) : Klinman et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In the claims:

Claim 1 is corrected to read:

1. A substantially pure or isolated stabilized oligodeoxynucleotide of between 18 and 30 nucleotides in length comprising any one of

5'-X₁X₂TGCATCGATGCAGGGGGG -3' (SEQ ID NO:12);

5'-X₁X₂TGCACCGGTGCAGGGGGG -3' (SEQ ID NO:13);

5'-X₁X₂TGCGTCGACGCAGGGGGG -3' (SEQ ID NO:14);

5'-X₁X₂TGCGCCGGCGCAGGGGGG -3' (SEQ ID NO:17);

5'-GGTGCATCGATGCAGGGGGG -3' (SEQ ID NO: 1);

5'-GGTGCGTCGACGCAGGGGGG -3' (SEQ ID NO: 31);

5'-GGTGCACCGGTGCAGGGGGG -3' (SEQ ID NO: 2); or,

5'-GGTGCATCGATGCAGGGGG -3' (SEQ ID NO: 73).

Claim 7 is corrected to read:

7. The oligodeoxynucleotide delivery complex of claim 5, wherein the stabilized oligodeoxynucleotide and the targeting moiety are covalently linked.

MAILING ADDRESS OF SENDER:

Klarquist Sparkman, LLP One World Trade Center, Suite 1600 121 SW Salmon Street Portland, Oregon 97204 PATENT NO. 6,977,245 No. of add'l copies______ (@ .30 per page)

